LUCENTIS

Lucentis is a remedy that effectively treats exudative-hemorrhagic form of age-specific maculate degeneration. It’s main active component is ranibizumab which is a is a monoclonal antibody fragment to human endothelial growth factor A, it can actively express by Escherichia coli strain in a recombinant form.

Ranibizumab has the property to selectively bind to isoforms of vascular endothelial growth factor VEGF-A and VEGF-preventing interaction A and its endothelial cell surface receptor, leading to inhibition of proliferation and neovascularization of blood vessels. The ability of the Lucentis to suppress the growth of new blood vessels into the retina. That effectively slows down the progression of hemorrhagic exudative age-specific macular degeneration.

Superficial anesthesia of conjunctiva and cornea comes 30 seconds after instillation of the preparation and persists for about 15 minutes, after which the concentration of active substance in the corneal stroma begins to decline.